Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
:KURA
KURA Analyst Ratings
Strong Buy
11 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KURA Stock 12 Month Forecast
Average Price Target
$26.00
▲(187.29% Upside)
| Highest Price Target$40.00 | Average Price Target$26.00 | Lowest Price Target$11.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$27
Buy
198.34%
Upside
Reiterated
09/18/25
Barclays
$11
Buy
21.55%
Upside
Reiterated
09/18/25
Jefferies
$28
Buy
209.39%
Upside
Reiterated
09/18/25
TD Cowen
―
Buy
―
Reiterated
09/17/25
Wedbush
$36
Buy
297.79%
Upside
Reiterated
09/17/25
H.C. Wainwright
$40
Buy
341.99%
Upside
Reiterated
09/17/25
Promising Developments in Kura Oncology's FTI Programs Highlighted by Analyst Buy RatingValuation and impediments to achieving price target. We reiterate our Buy rating and $40 price target. Our valuation is currently driven by ziftomenib (79% contribution) for the AML opportunity, KO-286 for solid tumors (5% contribution) and tipifarnib/alpelisib (16% contribution) for the HNSCC opportunity. We highlight that potential upside exists by not including diabetes for ziftomenib, broader AML use, KO-286 broader visibility on tumor types, and future business development potential.
Leerink Partners
―
Buy
―
Reiterated
09/17/25
Citizens JMP
$24
Buy
165.19%
Upside
Reiterated
09/17/25
LifeSci Capital
$24
Buy
165.19%
Upside
Reiterated
09/16/25
Kura Oncology's Strategic Positioning and Promising Developments Justify Buy RatingDuring an analyst event today (SLIDES) ahead of upcoming ESMO data (see Our FTI ESMO 2025 PREVIEW), KURA reviewed preclinical data and mechanisc raonale on FTI + KRAS/PI3Ka/TKIs, which they believe could address >200k annual incident pts in the US.
Guggenheim
$7.95
Hold
-12.15%
Downside
Initiated
09/03/25
Mizuho Securities
$30
Buy
231.49%
Upside
Reiterated
08/18/25
BTIG
―
Hold
―
Reiterated
08/07/25
Cantor Fitzgerald
―
Buy
―
Reiterated
06/26/25
Scotiabank
$10→$8
Hold
-11.60%
Downside
Reiterated
06/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$27
Buy
198.34%
Upside
Reiterated
09/18/25
Barclays
$11
Buy
21.55%
Upside
Reiterated
09/18/25
Jefferies
$28
Buy
209.39%
Upside
Reiterated
09/18/25
TD Cowen
―
Buy
―
Reiterated
09/17/25
Wedbush
$36
Buy
297.79%
Upside
Reiterated
09/17/25
H.C. Wainwright
$40
Buy
341.99%
Upside
Reiterated
09/17/25
Promising Developments in Kura Oncology's FTI Programs Highlighted by Analyst Buy RatingValuation and impediments to achieving price target. We reiterate our Buy rating and $40 price target. Our valuation is currently driven by ziftomenib (79% contribution) for the AML opportunity, KO-286 for solid tumors (5% contribution) and tipifarnib/alpelisib (16% contribution) for the HNSCC opportunity. We highlight that potential upside exists by not including diabetes for ziftomenib, broader AML use, KO-286 broader visibility on tumor types, and future business development potential.
Leerink Partners
―
Buy
―
Reiterated
09/17/25
Citizens JMP
$24
Buy
165.19%
Upside
Reiterated
09/17/25
LifeSci Capital
$24
Buy
165.19%
Upside
Reiterated
09/16/25
Kura Oncology's Strategic Positioning and Promising Developments Justify Buy RatingDuring an analyst event today (SLIDES) ahead of upcoming ESMO data (see Our FTI ESMO 2025 PREVIEW), KURA reviewed preclinical data and mechanisc raonale on FTI + KRAS/PI3Ka/TKIs, which they believe could address >200k annual incident pts in the US.
Guggenheim
$7.95
Hold
-12.15%
Downside
Initiated
09/03/25
Mizuho Securities
$30
Buy
231.49%
Upside
Reiterated
08/18/25
BTIG
―
Hold
―
Reiterated
08/07/25
Cantor Fitzgerald
―
Buy
―
Reiterated
06/26/25
Scotiabank
$10→$8
Hold
-11.60%
Downside
Reiterated
06/04/25
Best Analysts Covering Kura Oncology
1 Month
xxx
Success Rate
13/21 ratings generated profit
Average Return
+2.02%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +2.02% per trade.
3 Months
xxx
Success Rate
25/43 ratings generated profit
Average Return
+10.92%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +10.92% per trade.
1 Year
Success Rate
10/19 ratings generated profit
Average Return
+20.67%
reiterated a buy rating 12 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +20.67% per trade.
2 Years
xxx
Success Rate
22/43 ratings generated profit
Average Return
+23.91%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 51.16% of your transactions generating a profit, with an average return of +23.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KURA Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Aug 25
Sep 25
Strong Buy
23
22
35
37
29
Buy
3
4
10
11
10
Hold
7
5
7
7
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
31
52
55
43
Each month's total comprises the sum of three months' worth of ratings.
KURA Financial Forecast
KURA Stock Forecast FAQ
What is KURA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kura Oncology’s 12-month average price target is 26.00.
What is KURA’s upside potential, based on the analysts’ average price target?
Kura Oncology has 187.29% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KURA a Buy, Sell or Hold?
Kura Oncology has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
What is Kura Oncology’s price target?
The average price target for Kura Oncology is 26.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $11.00. The average price target represents 187.29% Increase from the current price of $9.05.
The highest analyst price target is $40.00 ,the lowest forecast is $11.00. The average price target represents 187.29% Increase from the current price of $9.05.
What do analysts say about Kura Oncology?
Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of KURA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.